Gilead execs flag trial failures for Sjögren’s and lupus drugs — while swapping out a favorite HIV program of top analyst
There’s more bad news on the Sjögren’s disease front today, after Gilead execs acknowledged in their Q3 call with analysts that their trio of drugs — including their top pipeline drug filgotinib — had failed mid-stage tests.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.